Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glycine modulators in schizophrenia.

Daniel C Javitt1

  • 1Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg 10962, USA. Javitt@nid.rfmh.org

Current Opinion in Investigational Drugs (London, England : 2000)
|August 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

Differential deficits in pattern- versus flash-visual evoked potentials in schizophrenia: relationship to subcortical visual systems, pulvinar nucleus and cognition.

Frontiers in neuroimaging·2026
Same author

Serotonin type 3 receptor (5-HT<sub>3</sub>R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Opposite sides of different coins: near-diametrical opposition of physiological indices of reduced accuracy of face emotion recognition in schizophrenia and autism spectrum disorders.

Frontiers in neuroimaging·2026
Same author

Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers: A Disordinal Effect.

Biological psychiatry·2026
Same author

Virtual Neuronavigation for Parcel-guided TMS.

medRxiv : the preprint server for health sciences·2025

N-methyl-D-aspartate (NMDA) receptor dysfunction is implicated in schizophrenia. Glycine transport inhibitors (GTIs) show promise for treating negative and cognitive symptoms by modulating NMDA receptors.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • N-methyl-D-aspartate (NMDA) receptor dysfunction is a key factor in schizophrenia pathophysiology.
  • Negative and cognitive symptoms of schizophrenia remain challenging to treat.
  • Glycine-site agonists show potential for symptom amelioration.

Purpose of the Study:

  • To explore the therapeutic potential of targeting NMDA receptors for schizophrenia.
  • To investigate glycine transport inhibitors (GTIs) as a novel treatment strategy.

Main Methods:

  • Review of recent studies on NMDA/glycine-site modulators.
  • Examination of preclinical data on glycine transport inhibitors (GTIs).

Main Results:

Related Experiment Videos

  • Glycine, D-serine, and D-cycloserine (glycine-site agonists) demonstrated effectiveness in small clinical trials.
  • Glycine levels in the brain are regulated by GLYT1 glycine transporters.
  • GTIs exhibit preclinical behavioral effects comparable to glycine or D-serine.

    • Conclusions:

    • NMDA receptor modulation offers a promising therapeutic avenue for schizophrenia.
    • Glycine transport inhibitors (GTIs) represent a potential next-generation treatment for persistent negative and cognitive symptoms of schizophrenia.